CY1122592T1 - Μη-στεροειδικοι διαμορφωτες υποδοχεα γλυκοκορτικοειδους για τοπικη χορηγηση φαρμακευτικων ουσιων - Google Patents

Μη-στεροειδικοι διαμορφωτες υποδοχεα γλυκοκορτικοειδους για τοπικη χορηγηση φαρμακευτικων ουσιων

Info

Publication number
CY1122592T1
CY1122592T1 CY20201100117T CY201100117T CY1122592T1 CY 1122592 T1 CY1122592 T1 CY 1122592T1 CY 20201100117 T CY20201100117 T CY 20201100117T CY 201100117 T CY201100117 T CY 201100117T CY 1122592 T1 CY1122592 T1 CY 1122592T1
Authority
CY
Cyprus
Prior art keywords
compounds
alkyl
glucocortico
steroid
drugs
Prior art date
Application number
CY20201100117T
Other languages
English (en)
Inventor
Patrick Stephen Johnson
Kevin Neil Dack
Krister Henriksson
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of CY1122592T1 publication Critical patent/CY1122592T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένωση σύμφωνα με τον τύπο (Ι) όπου η R1 επιλέγεται από την ομάδα που αποτελείται από 5- και 6-μελές ετεροαρύλιο, (C1-C6)αλκύλιο, (C3-C6)κυκλοαλκύλιο, (4-6)μελές ετεροκυκλοαλκύλιο και φαινύλιο· η R2 επιλέγεται από (C1-C3)αλκύλιο και αλογονο(C1-C3)αλκύλιο· η R3 επιλέγεται από φαινύλιο, 5-μελές ετεροαρύλιο και 6-μελές ετεροαρύλιο· η R4 επιλέγεται από υδρογόνο, αλογόνο, (C1-C4)αλκύλιο και αλογονο(C1-C4)αλκύλιo· η Χ1 επιλέγεται από CΗ, C(Rb) και Ν, η Χ2 επιλέγεται από CΗ και Ν· η Υ επιλέγεται από -ΝΗ- και -Ο-· m είναι 0 ή 1· n είναι 0 ή 1· L αντιπροσωπεύει δεσμό, -Ο-, -ΝΗ- ή -Ν(Rc)-· ή αποδεκτά από φαρμακευτική άποψη άλατα, συμπλέγματα ενυδάτωσης ή συμπλέγματα επιδιαλύτωσης αυτής. Η εφεύρεση σχετίζεται περαιτέρω με ενδιάμεσα για την παρασκευή των εν λόγω ενώσεων, με τις εν λόγω ενώσεις για χρήση στη θεραπεία, με φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω ενώσεις, με μεθόδους αγωγής παθήσεων με τις εν λόγω ενώσεις, και με τη χρήση των εν λόγω ενώσεων στην παραγωγή φαρμάκων.
CY20201100117T 2015-09-15 2020-02-06 Μη-στεροειδικοι διαμορφωτες υποδοχεα γλυκοκορτικοειδους για τοπικη χορηγηση φαρμακευτικων ουσιων CY1122592T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15185283 2015-09-15
PCT/EP2016/071580 WO2017046096A1 (en) 2015-09-15 2016-09-13 Non-steroidal glucocorticoid receptor modulators for local drug delivery

Publications (1)

Publication Number Publication Date
CY1122592T1 true CY1122592T1 (el) 2021-01-27

Family

ID=54145684

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100117T CY1122592T1 (el) 2015-09-15 2020-02-06 Μη-στεροειδικοι διαμορφωτες υποδοχεα γλυκοκορτικοειδους για τοπικη χορηγηση φαρμακευτικων ουσιων

Country Status (27)

Country Link
US (1) US10494363B2 (el)
EP (1) EP3350175B1 (el)
JP (1) JP6749399B2 (el)
KR (1) KR20180050408A (el)
CN (1) CN108368094B (el)
AU (1) AU2016323254B2 (el)
CA (1) CA2996819A1 (el)
CY (1) CY1122592T1 (el)
DK (1) DK3350175T3 (el)
ES (1) ES2770303T3 (el)
HK (1) HK1258975A1 (el)
HR (1) HRP20200130T1 (el)
HU (1) HUE048410T2 (el)
IL (1) IL257549B (el)
LT (1) LT3350175T (el)
MX (1) MX2018003250A (el)
MY (1) MY192275A (el)
PL (1) PL3350175T3 (el)
PT (1) PT3350175T (el)
RS (1) RS60007B1 (el)
RU (1) RU2731618C2 (el)
SA (1) SA518391118B1 (el)
SI (1) SI3350175T1 (el)
TW (1) TWI733696B (el)
UA (1) UA120980C2 (el)
WO (1) WO2017046096A1 (el)
ZA (1) ZA201801306B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210119980A (ko) 2019-01-22 2021-10-06 아크리베스 바이오메디컬 게엠베하 손상된 피부 상처를 치료하기 위한 선택적 글루코코르티코이드 수용체 개질제
CN116535324A (zh) * 2023-07-07 2023-08-04 广东嘉博制药有限公司 一种苏式构型盐酸甲氧明的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
TWI370129B (en) * 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
AU2008211622B2 (en) * 2007-02-02 2012-04-19 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
TWI445705B (zh) * 2008-05-20 2014-07-21 Astrazeneca Ab 經苯基及苯并二基取代之吲唑衍生物
EP2685827B1 (en) * 2011-03-18 2016-02-03 Corcept Therapeutics, Inc. Pyrimidine cyclohexyl glucocorticoid receptor modulators

Also Published As

Publication number Publication date
CA2996819A1 (en) 2017-03-23
IL257549A (en) 2018-04-30
EP3350175B1 (en) 2019-11-06
RU2731618C2 (ru) 2020-09-07
CN108368094B (zh) 2021-07-02
IL257549B (en) 2021-01-31
UA120980C2 (uk) 2020-03-10
US10494363B2 (en) 2019-12-03
MX2018003250A (es) 2018-08-21
SI3350175T1 (sl) 2020-04-30
PL3350175T3 (pl) 2020-07-27
RU2018113438A3 (el) 2020-01-24
LT3350175T (lt) 2020-02-25
PT3350175T (pt) 2020-02-19
ES2770303T3 (es) 2020-07-01
JP6749399B2 (ja) 2020-09-02
TW201720814A (zh) 2017-06-16
HRP20200130T1 (hr) 2020-05-15
RU2018113438A (ru) 2019-10-16
AU2016323254A1 (en) 2018-03-08
HK1258975A1 (zh) 2019-11-22
ZA201801306B (en) 2019-07-31
KR20180050408A (ko) 2018-05-14
MY192275A (en) 2022-08-16
TWI733696B (zh) 2021-07-21
HUE048410T2 (hu) 2020-07-28
AU2016323254B2 (en) 2020-08-20
EP3350175A1 (en) 2018-07-25
CN108368094A (zh) 2018-08-03
SA518391118B1 (ar) 2021-07-14
WO2017046096A1 (en) 2017-03-23
JP2018528270A (ja) 2018-09-27
US20180258080A1 (en) 2018-09-13
DK3350175T3 (da) 2020-02-03
RS60007B1 (sr) 2020-04-30

Similar Documents

Publication Publication Date Title
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
CY1118739T1 (el) Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch
CY1120342T1 (el) Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου
PH12020551821A1 (en) Novel compounds
ECSP22046699A (es) Inhibidores de kras g12c
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1117428T1 (el) Φαρμακευτικες ενωσεις
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
CY1124970T1 (el) Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικου
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR087309A1 (es) Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
CY1122744T1 (el) Ενωσεις τετρακυκλινης
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
AR055744A1 (es) Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
CY1122592T1 (el) Μη-στεροειδικοι διαμορφωτες υποδοχεα γλυκοκορτικοειδους για τοπικη χορηγηση φαρμακευτικων ουσιων
CY1119296T1 (el) Ενωση δικαρβοξυλικου οξεος